Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 11
Submit an article Journal homepage
263
Views
38
CrossRef citations to date
0
Altmetric
Workshop Reviews (Deauville, April 2009)

Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation – where do we stand?

Michel MeignanNuclear Medicine Department, Henri Mondor Hospital, AP-HP, Paris 12 University, Créteil, FranceCorrespondence[email protected]
,
Emmanuel IttiNuclear Medicine Department, Henri Mondor Hospital, AP-HP, Paris 12 University, Créteil, France
,
Andrea GallaminiHematology Department and BMT Unit, Az. Ospedaliera S Croce e Carle, Cuneo, Italy
&
Corinne HaiounHematology Department, Henri Mondor Hospital, AP-HP, Paris 12 University, Créteil, France
Pages 1753-1756 | Received 27 Aug 2009, Accepted 01 Sep 2009, Published online: 28 Oct 2009

References

  • Jerusalem G, Beguin Y, Fassotte MF, et al Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin lymphoma. Haematologica 2000;85:613–618.
  • Spaepen K, Stroobants S, Dupont P, et al Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin lymphoma. Ann Oncol 2002;13:1356–1363.
  • Haioun C, Itti E, Rahmouni A, et al [18F]Fluoro-2-deoxy-d-glucose positron emission tomography (FDG_PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376–1381.
  • Mikhaeel NG, Hutchings M, Fields PA, et al FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16: 1514–1523.
  • Kostakoglu L, Coleman M, Leonard JP, et al PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002;43: 1018–1027.
  • Cheson B. The case against heavy PETing. J Clin Oncol 2009;27:1742–1743.
  • Terasawa T, Lau J, Bardet S, et al Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906–1914.
  • Juweid ME, Stroobants S, Hoekstra OS, et al Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007;25: 571–578.
  • Han HS, Escalon MP, Hsiao B, et al High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’ lymphoma treated with rituximab-containing regimens. Ann Oncol 2009;20:309–318.
  • Kostakoglu L. Early prediction of response to therapy: the clinical implications in Hodgkin and non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2008;35:1413–1420.
  • Dupuis J, Gaulard P, Hemery F, et al Respective prognostic values of germinal center phenotype and early (18)Fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma. Haematologica 2007;92:778–783.
  • Lin C, Itti E, Haioun C, et al Early 18F-FDG-PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007;48:1626–1632.
  • Dupuis J, Itti E, Rahmouni A, et al Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the international workshop criteria. Ann Oncol 2009. 20:503–507.
  • Itti E, Lin C, Dupuis J, et al Prognostic value of interim 18f-FDG-PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009;50:527–533.
  • Gallamini A, Hutchings M, Avigdor A, et al Early interim PET scan in Hodgkin lymphoma: where do we stand. Leuk Lymphoma 2008;49:659–662.
  • Horning SJ, Juweid M, Schoder H, et al Interim positron emission tomography (PET) in diffuse large B-cell lymphoma: independent expert nuclear medicine evaluation of ECOG 3404. Blood 2008;112:372 (Abstract).
  • Meignan M, Itti E, Bardet S, et al Development and application of a real-time on-line blinded independent central review of interim pet scans to determine treatment allocation in lymphoma trials. J Clin Oncol 2009;27:2739–2741.
  • Kasamon YL, Wahl RL. FDG PET and risk-adapted therapy in Hodgkins and non-Hodgkin’ lymphoma. Curr Opin Oncol 2008;20:206–219.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.